OPEN END TURBO OPTIONSSCHEIN LONG - ASTRAZENECA | Real-time BOERSE MUENCHEN 05:56:31 18/06/2024 pm IST | ||
| 7.591 EUR | -0.67% |
|
| Current month | +4.11% | ||
| 1 month | +6.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 18/24/18 | 7.591 | -0.67% |
| 17/24/17 | 7.642 | -1.52% |
| 14/24/14 | 7.76 | +1.17% |
| 13/24/13 | 7.67 | -0.13% |
| 12/24/12 | 7.68 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 18, 2024 at 05:56 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GP743N |
| ISIN | DE000GP743N4 |
| Date issued | 26/06/2023 |
| Strike | 5,991 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.67 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.87 € |
|---|---|
| Lowest since issue | 4.17 € |
| Spread | 0.01 € |
| Spread % | 0.13% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7
USD
Average target price
174.4
USD
Spread / Average Target
+10.62%
- Stock Market
- Certificates
- Certificat
